Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 9/20 | 0.45 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.43 |
| ▸ | ULK1 | O75385 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 2/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.42 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 3/20 | 0.42 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | STK16 | O75716 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.42 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.42 |
| ▸ | MARK3 | P27448 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955870 | 1.00 | AURKA (0.46) | AURKARPS6KB1SYKULK2ULK1 | |
| SCHEMBL14976339 | 0.90 | RPS6KB1 (0.46) | AURKARPS6KB1SYKULK2ULK1 | |
| SCHEMBL14956331 | 0.90 | SYK (0.47) | AURKARPS6KB1SYKPLK4TBK1 | |
| SCHEMBL14956333 | 0.90 | SYK (0.47) | AURKARPS6KB1SYKPLK4TBK1 | |
| SCHEMBL14975962 | 0.80 | SYK (0.49) | AURKARPS6KB1SYKPLK4TBK1 | |
| SCHEMBL14956375 | 0.77 | SYK (0.61) | SYK | |
| SCHEMBL14956373 | 0.77 | SYK (0.61) | SYK | |
| SCHEMBL14956600 | 0.75 | SYK (0.51) | RPS6KB1SYKPLK4CSF1RTYK2 | |
| SCHEMBL14956597 | 0.75 | SYK (0.51) | RPS6KB1SYKPLK4CSF1RTYK2 | |
| SCHEMBL14955685 | 0.75 | SYK (0.50) | RPS6KB1SYKULK1PLK4CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013078466-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | SYK, ZAP70, LCK | AURKA 330/4885RPS6KB1 387/4885SYK 1/4885 |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | SYK, ZAP70, LCK | AURKA 330/4885RPS6KB1 387/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.